169 related articles for article (PubMed ID: 34188921)
1. Drug-induced immune-mediated thrombocytopenia secondary to durvalumab use.
Dougherty SC; Lynch AC; Hall RD
Clin Case Rep; 2021 Jun; 9(6):e04227. PubMed ID: 34188921
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN
Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661
[TBL] [Abstract][Full Text] [Related]
3. Acquired amegakaryocytic thrombocytopenia after durvalumab administration.
Suyama T; Hagihara M; Kubota N; Osamura Y; Shinka Y; Miyao N
J Clin Exp Hematop; 2021 Mar; 61(1):53-57. PubMed ID: 33431742
[TBL] [Abstract][Full Text] [Related]
4. An update on pediatric ITP: differentiating primary ITP, IPD, and PID.
Grace RF; Lambert MP
Blood; 2022 Aug; 140(6):542-555. PubMed ID: 34479363
[TBL] [Abstract][Full Text] [Related]
5. Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP.
Weitz IC; Liebman HA
Br J Haematol; 2023 Oct; 203(1):96-100. PubMed ID: 37735550
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia.
Wang X; Bi H; Liu L; Liu Y; Yin L; Yao J; Yu J; Tao W; Wei Y; Li Y; Yin L; Mu H; Du Y; Zhou Z
Platelets; 2023 Dec; 34(1):2271568. PubMed ID: 37941414
[TBL] [Abstract][Full Text] [Related]
8. The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy.
Moulinet T; Moussu A; Pierson L; Pagliuca S
Blood Rev; 2024 Jan; 63():101141. PubMed ID: 37980261
[TBL] [Abstract][Full Text] [Related]
9. Severe immune thrombocytopenia following COVID-19 vaccination (Moderna) and immune checkpoint inhibitor.
Chong KM; Yang CY; Lin CC; Lien WC
Am J Emerg Med; 2022 Jun; 56():395.e1-395.e3. PubMed ID: 35339338
[TBL] [Abstract][Full Text] [Related]
10. [Idiopathic thrombocytopenic purpura in children].
Gebauer E; Vijatov G
Med Pregl; 1998; 51(3-4):127-34. PubMed ID: 9611955
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced thrombocytopenia: development of a novel NOD/SCID mouse model to evaluate clearance of circulating platelets by drug-dependent antibodies and the efficacy of IVIG.
Liang SX; Pinkevych M; Khachigian LM; Parish CR; Davenport MP; Chong BH
Blood; 2010 Sep; 116(11):1958-60. PubMed ID: 20566900
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic approaches to secondary immune thrombocytopenic purpura.
Bussel JB
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S44-58. PubMed ID: 19245934
[TBL] [Abstract][Full Text] [Related]
13. Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report.
Makiguchi T; Tanaka H; Kamata K; Taima K; Kurose A; Tasaka S
Thorac Cancer; 2021 Oct; 12(20):2811-2814. PubMed ID: 34405563
[TBL] [Abstract][Full Text] [Related]
14. Attempt to improve the diagnosis of immune thrombocytopenia by combined use of two different platelet autoantibodies assays (PAIgG and MACE).
Fabris F; Scandellari R; Randi ML; Carraro G; Luzzatto G; Girolami A
Haematologica; 2002 Oct; 87(10):1046-52. PubMed ID: 12368159
[TBL] [Abstract][Full Text] [Related]
15. Monocyte-platelet interaction in immune and nonimmune thrombocytopenia.
Saleh MN; Moore DL; Lee JY; LoBuglio AF
Blood; 1989 Sep; 74(4):1328-31. PubMed ID: 2765665
[TBL] [Abstract][Full Text] [Related]
16. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
17. Differentiation of autoimmune thrombocytopenia from thrombocytopenia associated with immune complex disease: systemic lupus erythematosus, hepatitis-cirrhosis, and HIV-1 infection by platelet and serum immunological measurements.
Samuel H; Nardi M; Karpatkin M; Hart D; Belmont M; Karpatkin S
Br J Haematol; 1999 Jun; 105(4):1086-91. PubMed ID: 10554825
[TBL] [Abstract][Full Text] [Related]
18. Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy.
Assi HA; Asch AS; Machiorlatti M; Vesely SK; Ibrahimi S
Future Sci OA; 2020 Jun; 6(7):FSO581. PubMed ID: 32802390
[TBL] [Abstract][Full Text] [Related]
19. Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review.
Fu S; Wang T; Xu F
J Oncol Pharm Pract; 2021 Sep; 27(6):1548-1552. PubMed ID: 33435825
[TBL] [Abstract][Full Text] [Related]
20. Severe immune thrombocytopenia following diphtheria, tetanus, pertussis and polio vaccination in a 36-year-old Caucasian woman: a case report.
Küster O; Schmohl J; Greiner J; Storz MA
Eur J Med Res; 2022 May; 27(1):63. PubMed ID: 35505368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
